HIV and Malignancy Scientific Working Group

$30,169P30FY2025AINIH

Harvard University, Cambridge MA

Investigators

Linked publications & trials

Paper 39723835 Paper 39659298 Paper 39636888 Paper 39502784 Paper 39470739 Paper 39465466 Paper 39401365 Paper 39320890 Paper 39306630 Paper 39272091 Paper 39248459 Paper 39231105 Paper 39215251 Paper 39192226 Paper 39174703 Paper 39086468 Paper 39079827 Paper 39074163 Paper 39037240 Paper 39005324 Paper 38985403 Paper 38947072 Paper 38895338 Paper 38883786 Paper 38861653 Paper 38854997 Paper 38852087 Paper 38790897 Paper 38746144 Paper 38744864 Paper 38699317 Paper 38670113 Paper 38653235 Paper 38648528 Paper 38609695 Paper 38596653 Paper 38585939 Paper 38551350 Paper 38539112 Paper 38498515 Paper 38474837 Paper 38462755 Paper 38444112 Paper 38440980 Paper 38347453 Paper 38316748 Paper 38291019 Paper 38281251 Paper 38266109 Paper 38245684 Paper 38236978 Paper 38232978 Paper 38228564 Paper 38216186 Paper 38160309 Paper 38123897 Paper 38112296 Paper 38091449 Paper 38032748 Paper 38018105 Paper 37977197 Paper 37963018 Paper 37957382 Paper 37956428 Paper 37937312 Paper 37916471 Paper 37910437 Paper 37862075 Paper 37857692 Paper 37846528 Paper 37843905 Paper 37843832 Paper 37843685 Paper 37755897 Paper 37707858 Paper 37680484 Paper 37650767 Paper 37594960 Paper 37581929 Paper 37577493 Paper 37547804 Paper 37524973 Paper 37523048 Paper 37496609 Paper 37461715 Paper 37425934 Paper 37419138 Paper 37401992 Paper 37398278 Paper 37325961 Paper 37319250 Paper 37279602 Paper 37229763 Paper 37228375 Paper 37217466 Paper 37205767 Paper 37198608 Paper 37179294 Paper 37163616 Paper 37144613

Abstract

PROJECT SUMMARY/ABSTRACT: HIV and Malignancy Scientific Working Group The overall goal of the HU CFAR HIV & Malignancy Scientific Working Group (SWG) is to address this growing burden of malignancies among PLWH by 1) engaging community partners, clinicians, and scientists; 2) facilitating clinical and specimen data synthesis and interpretation; and 3) supporting investigators, especially Early Career Investigators (ECIs). Through these activities, we will accelerate the discovery of mechanisms and interventions to prevent and treat cancers among PLWH. A key theme through these three aims is catalyzing translational research and identifying priorities at each translational stage, and guiding the process to ultimately have an impact on individual and population-level health. The HU CFAR is uniquely positioned to leverage experts, clinical and basic science resources, and data and specimens to address scientific questions about HIV and malignancies.

View original record on NIH RePORTER →